Table 2.
Summary of the case series and case reports regarding clobazam efficacy in status epilepticus
| Author (year) | Study type | n | Sex | Age (years) | History of seizures/epilepsy | SE type | Clobazam dose | Order of initiation (excluding initial BDZ) | Time from SE onset to clobazam initiation (day) | SE control in CLB responders | Response |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Corman et al.19 (1998) | Case series | 4 |
M (n = 1) F (n = 3) |
49 (30–71) |
Yes 2 No 2 |
RSE FSE 4 (100%) |
Single dose of 60–70 mg to induce remission MD 20 mg/day in one case |
2nd–4th | 1–2 | Seizure activity controlled within 2 h in 3 cases (75%) and 2 days in the 4th case | Yes n = 4 (100%) |
|
Tinuper et al.18 (1986). Note: Gastaut et al.25 (1984) reported the same findings in French |
Case series | 16 |
M (n = 6) F (n = 10) |
22 (3–62) | Yes 100% |
Absence SE 6 (38%) Myoclonic Absence SE 1 (6%) Myoclonic SE 1 (6%) Tonic SE 1 (6%) FSE 7 (44%) |
Single dose: 1.08 (0.51.70) mg/kg | NR | NR | Seizure activity controlled within 30 min in 15 cases (94%) and 7 h in one patient | YES n = 16 (100%) |
| Mutis et al.24 (2017) | Case report | 1 | F | 62 | No |
NCSE FSE |
20 mg/day in 2 divided doses | 2nd | NR | Added with lacosamide | Yes |
|
Sawicka et al.26 (2016) (Abstract) |
Case report | 1 | F | 18 | No | RSE | NR | NR | NR | CLB was part of multidrug regimen | Yes – Not clear if it had added benefit |
| Tran et al.27 (2013) | Case report | 1 | M | 49 | No | FSE | NR | NR | NR | CLB was part of multidrug regimen | No |
| Reuber et al.28 (2002) | Case report | 1 | F | 68 | No | CPSE | 30 mg daily | 2nd | NR | N/A | No |
| Murchison et al.29 (1995) | Case report | 1 | F | 31 | Yes | NCSE | 10 mg daily | 2nd | NR | Remission in 3 days | Yes |
BDZ, benzodiazepine; CLB, clobazam; CPSE, complex partial status epilepticus; FSE, focal status epilepticus; MD, maintenance dose; N/A, not applicable; NCSE, nonconvulsive status epilepticus; NR, not reported; RSE, refractory status epilepticus; SE, status epilepticus.